Studies of White Blood Cells Derived From HHT Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2008 by Imperial College London.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
British Heart Foundation
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00230633
First received: September 29, 2005
Last updated: August 12, 2008
Last verified: August 2008
  Purpose

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels. We propose to take blood samples from patients with HHT, and culture white blood cells that express the proteins mutated in HHT, namely endoglin and ALK-1. We will study the properties of these cells which will involve their growth in media prompting different types of differentiation, or infection of cell lines with Epstein Barr virus to provide cell lines which can be repeatedly studied. It is anticipated that DNA, mRNA and proteins will be extracted from these cells for study of white cell responses and association with expression levels of endoglin and ALK-1 We hypothesize that these cells which express "half-normal" endoglin or ALK-1 will show altered protein synthetic differences when compared to normal white blood cells. We anticipate that that these findings may help to explain aspects of the HHT disease phenotype.


Condition
Telangiectasia, Hereditary Hemorrhagic

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Studies of White Blood Cells Derived From HHT Patients

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Estimated Enrollment: 200
Study Start Date: April 2002
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with HHT, and family members

Exclusion Criteria:

  • Unable to provide informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230633

Contacts
Contact: Claire L Shovlin 0208 383 1000 c.shovlin@imperial.ac.uk

Locations
United Kingdom
Imperial College Hammersmith Campus Recruiting
London, United Kingdom, W12 0NN
Contact: Claire L Shovlin    0208 383 1000    c.shovlin@imperial.ac.uk   
Principal Investigator: Claire L Shovlin         
Sponsors and Collaborators
Imperial College London
British Heart Foundation
Investigators
Principal Investigator: Claire L Shovlin Imperial College London
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00230633     History of Changes
Other Study ID Numbers: IC/CLS3
Study First Received: September 29, 2005
Last Updated: August 12, 2008
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Telangiectasia, Hereditary Hemorrhagic
Telangiectasis
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Hemorrhagic Disorders
Hematologic Diseases
Vascular Malformations
Cardiovascular Abnormalities
Congenital Abnormalities

ClinicalTrials.gov processed this record on September 11, 2014